CTMX
CytomX Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.71
+0.82%Margins
Gross margin
98.6%
EBITDA margin
-427.4%
EBIT margin
-476.2%
Net margin
-435.2%
FCF margin
-450.7%
-26.4%
Return on equity
-20.9%
Return on assets
-28.3%
Return on invested capital
0.05x
Asset turnover
-$82.4M
Cash from operations
$1.52
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026